Condition
Mucoepidermoid Carcinoma
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Unknown1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04249947Phase 1Terminated
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
NCT01586767Not ApplicableUnknown
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
NCT03602079Phase 1Completed
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Showing all 3 trials